Exact Mass: 469.1880568
Exact Mass Matches: 469.1880568
Found 123 metabolites which its exact mass value is equals to given mass value 469.1880568
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
His Asn Ala Glu
C18H27N7O8 (469.19210219999997)
Asn Ala His Glu
C18H27N7O8 (469.19210219999997)
Gln Ala His Asp
C18H27N7O8 (469.19210219999997)
C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)
C24H27N3O7 (469.18489120000004)
3-hydroxy-2-[[1-[2-[(4-hydroxybenzoyl)amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]benzoic acid
C24H27N3O7 (469.18489120000004)
Ala Asp His Gln
C18H27N7O8 (469.19210219999997)
Ala Asp Gln His
C18H27N7O8 (469.19210219999997)
Ala Glu His Asn
C18H27N7O8 (469.19210219999997)
Ala Glu Asn His
C18H27N7O8 (469.19210219999997)
Ala His Asp Gln
C18H27N7O8 (469.19210219999997)
Ala His Glu Asn
C18H27N7O8 (469.19210219999997)
Ala His Asn Glu
C18H27N7O8 (469.19210219999997)
Ala His Gln Asp
C18H27N7O8 (469.19210219999997)
Ala Asn Glu His
C18H27N7O8 (469.19210219999997)
Ala Asn His Glu
C18H27N7O8 (469.19210219999997)
Ala Gln Asp His
C18H27N7O8 (469.19210219999997)
Ala Gln His Asp
C18H27N7O8 (469.19210219999997)
Asp Ala His Gln
C18H27N7O8 (469.19210219999997)
Asp Ala Gln His
C18H27N7O8 (469.19210219999997)
Asp His Ala Gln
C18H27N7O8 (469.19210219999997)
Asp His Gln Ala
C18H27N7O8 (469.19210219999997)
Asp Gln Ala His
C18H27N7O8 (469.19210219999997)
Asp Gln His Ala
C18H27N7O8 (469.19210219999997)
Glu Ala His Asn
C18H27N7O8 (469.19210219999997)
Glu Ala Asn His
C18H27N7O8 (469.19210219999997)
Glu Gly His Gln
C18H27N7O8 (469.19210219999997)
Glu Gly Gln His
C18H27N7O8 (469.19210219999997)
Glu His Ala Asn
C18H27N7O8 (469.19210219999997)
Glu His Gly Gln
C18H27N7O8 (469.19210219999997)
Glu His Asn Ala
C18H27N7O8 (469.19210219999997)
Glu His Gln Gly
C18H27N7O8 (469.19210219999997)
Glu Asn Ala His
C18H27N7O8 (469.19210219999997)
Glu Asn His Ala
C18H27N7O8 (469.19210219999997)
Glu Gln Gly His
C18H27N7O8 (469.19210219999997)
Glu Gln His Gly
C18H27N7O8 (469.19210219999997)
Gly Glu His Gln
C18H27N7O8 (469.19210219999997)
Gly Glu Gln His
C18H27N7O8 (469.19210219999997)
Gly His Glu Gln
C18H27N7O8 (469.19210219999997)
Gly His Gln Glu
C18H27N7O8 (469.19210219999997)
Gly Gln Glu His
C18H27N7O8 (469.19210219999997)
Gly Gln His Glu
C18H27N7O8 (469.19210219999997)
His Ala Asp Gln
C18H27N7O8 (469.19210219999997)
His Ala Glu Asn
C18H27N7O8 (469.19210219999997)
His Ala Asn Glu
C18H27N7O8 (469.19210219999997)
His Ala Gln Asp
C18H27N7O8 (469.19210219999997)
His Asp Ala Gln
C18H27N7O8 (469.19210219999997)
His Asp Gln Ala
C18H27N7O8 (469.19210219999997)
His Glu Ala Asn
C18H27N7O8 (469.19210219999997)
His Glu Gly Gln
C18H27N7O8 (469.19210219999997)
His Glu Asn Ala
C18H27N7O8 (469.19210219999997)
His Glu Gln Gly
C18H27N7O8 (469.19210219999997)
His Gly Glu Gln
C18H27N7O8 (469.19210219999997)
His Gly Gln Glu
C18H27N7O8 (469.19210219999997)
His Asn Glu Ala
C18H27N7O8 (469.19210219999997)
His Gln Ala Asp
C18H27N7O8 (469.19210219999997)
His Gln Asp Ala
C18H27N7O8 (469.19210219999997)
His Gln Glu Gly
C18H27N7O8 (469.19210219999997)
His Gln Gly Glu
C18H27N7O8 (469.19210219999997)
Asn Ala Glu His
C18H27N7O8 (469.19210219999997)
Asn Glu Ala His
C18H27N7O8 (469.19210219999997)
Asn Glu His Ala
C18H27N7O8 (469.19210219999997)
Asn His Ala Glu
C18H27N7O8 (469.19210219999997)
Asn His Glu Ala
C18H27N7O8 (469.19210219999997)
Asn Ser Ser Tyr
C19H27N5O9 (469.18086919999996)
Asn Ser Tyr Ser
C19H27N5O9 (469.18086919999996)
Asn Tyr Ser Ser
C19H27N5O9 (469.18086919999996)
Gln Ala Asp His
C18H27N7O8 (469.19210219999997)
Gln Asp Ala His
C18H27N7O8 (469.19210219999997)
Gln Asp His Ala
C18H27N7O8 (469.19210219999997)
Gln Glu Gly His
C18H27N7O8 (469.19210219999997)
Gln Glu His Gly
C18H27N7O8 (469.19210219999997)
Gln Gly Glu His
C18H27N7O8 (469.19210219999997)
Gln Gly His Glu
C18H27N7O8 (469.19210219999997)
Gln His Ala Asp
C18H27N7O8 (469.19210219999997)
Gln His Asp Ala
C18H27N7O8 (469.19210219999997)
Gln His Glu Gly
C18H27N7O8 (469.19210219999997)
Gln His Gly Glu
C18H27N7O8 (469.19210219999997)
Ser Asn Ser Tyr
C19H27N5O9 (469.18086919999996)
Ser Asn Tyr Ser
C19H27N5O9 (469.18086919999996)
Ser Ser Asn Tyr
C19H27N5O9 (469.18086919999996)
Ser Ser Tyr Asn
C19H27N5O9 (469.18086919999996)
Ser Tyr Asn Ser
C19H27N5O9 (469.18086919999996)
Ser Tyr Ser Asn
C19H27N5O9 (469.18086919999996)
Tyr Asn Ser Ser
C19H27N5O9 (469.18086919999996)
Tyr Ser Asn Ser
C19H27N5O9 (469.18086919999996)
Tyr Ser Ser Asn
C19H27N5O9 (469.18086919999996)
NVP-BEZ235
N-(4-Hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)prolinamide
C24H27N3O7 (469.18489120000004)
dimenhydrinate
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Dimenhydrinate is an orally active H1-antihistamine consisting of Diphenhydramine (HY-B0303) and 8-Chlorotheophylline. Dimenhydrinate is used to prevent nausea, vomiting, dizziness, and vertigo associated with motion sickness[1].
Almotriptan
C21H31N3O7S (469.18826160000003)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine. IC50: Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) Receptor Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors [1]. Almotriptan had a mild antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is probably of no clinical relevance. In addition, no effect on the respiratory system of conscious guinea pigs was observed following almotriptan treatment. These results indicate that almotriptan has a favourable safety profile with respect to the central nervous, renal and respiratory systems [2].
benzylpenicillin β-diethylaminoethyl ester hydrochloride
C22H32ClN3O4S (469.1801942000001)
Gandotinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylMethyl)-, 1,6-diacetate
C24H27N3O7 (469.18489120000004)
Mycophenolate mofetil hydrochloride
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents C471 - Enzyme Inhibitor > C2087 - Inosine Monophosphate Dehydrogenase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
(2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-1,4-benzoxazin-3-one
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
6-amino-1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-hydroxy-5-methyl-3,4-dihydro[4,4-bipyrimidine]-2,2(1H,3H)-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
2-[(2R,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(2R,3R,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2S,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(2S,3R,6S)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
1-[(2R,3S,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2R,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-(3-chlorophenyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(2S,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2R,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-(3-chlorophenyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(2R,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-deoxycytidine-thymidine dimer
C19H27N5O9 (469.18086919999996)
A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine and thymidine.
4-[({10-amino-10-benzyl-7,9,10a-trihydroxy-3-oxo-1h,2h,5h-pyrrolo[1,2-b]isoquinolin-5-yl}(hydroxy)methylidene)amino]butanoic acid
C24H27N3O7 (469.18489120000004)